View of Cost Minimization Analysis (CMA) of XELOX versus MFOLFOX6 in the treatment of colorectal cancer in a public hospital in Brazil | JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA